Cross-Neutralizing Activity Against Omicron Could Be Obtained in SARS-CoV-2 Convalescent Patients Who Received Two Doses of mRNA Vaccination
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant omicron is now under investigation. We evaluated cross-neutralizing activity against omicron in coronavirus disease 2019 (COVID-19) convalescent patients (n = 23) who had received 2 doses of an mRNA vaccination (BNT162b2 or mRNA-1273). Intriguingly, after the second vaccination, the neutralizing antibody titers of subjects against SARS-CoV-2 variants, including omicron, all became seropositive, and significant fold-increases (21.1-52.0) were seen regardless of the disease severity. Our findings thus demonstrate that 2 doses of mRNA vaccination to SARS-CoV-2 convalescent patients can induce cross-neutralizing activity against omicron.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:226 |
|---|---|
| Enthalten in: |
The Journal of infectious diseases - 226(2022), 8 vom: 17. Okt., Seite 1391-1395 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kurahashi, Yukiya [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Neutralizing |
|---|
| Anmerkungen: |
Date Completed 18.10.2022 Date Revised 04.12.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/infdis/jiac178 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM340409266 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM340409266 | ||
| 003 | DE-627 | ||
| 005 | 20231226005143.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/infdis/jiac178 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1134.xml |
| 035 | |a (DE-627)NLM340409266 | ||
| 035 | |a (NLM)35512332 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kurahashi, Yukiya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cross-Neutralizing Activity Against Omicron Could Be Obtained in SARS-CoV-2 Convalescent Patients Who Received Two Doses of mRNA Vaccination |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.10.2022 | ||
| 500 | |a Date Revised 04.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant omicron is now under investigation. We evaluated cross-neutralizing activity against omicron in coronavirus disease 2019 (COVID-19) convalescent patients (n = 23) who had received 2 doses of an mRNA vaccination (BNT162b2 or mRNA-1273). Intriguingly, after the second vaccination, the neutralizing antibody titers of subjects against SARS-CoV-2 variants, including omicron, all became seropositive, and significant fold-increases (21.1-52.0) were seen regardless of the disease severity. Our findings thus demonstrate that 2 doses of mRNA vaccination to SARS-CoV-2 convalescent patients can induce cross-neutralizing activity against omicron | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a convalescent | |
| 650 | 4 | |a cross-neutralizing antibody | |
| 650 | 4 | |a omicron | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 650 | 7 | |a N38TVC63NU |2 NLM | |
| 700 | 1 | |a Furukawa, Koichi |e verfasserin |4 aut | |
| 700 | 1 | |a Sutandhio, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Tjan, Lidya Handayani |e verfasserin |4 aut | |
| 700 | 1 | |a Iwata, Sachiyo |e verfasserin |4 aut | |
| 700 | 1 | |a Sano, Shigeru |e verfasserin |4 aut | |
| 700 | 1 | |a Tohma, Yoshiki |e verfasserin |4 aut | |
| 700 | 1 | |a Ohkita, Hiroyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Nakamura, Sachiko |e verfasserin |4 aut | |
| 700 | 1 | |a Nishimura, Mitsuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Arii, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Kiriu, Tatsunori |e verfasserin |4 aut | |
| 700 | 1 | |a Yamamoto, Masatsugu |e verfasserin |4 aut | |
| 700 | 1 | |a Nagano, Tatsuya |e verfasserin |4 aut | |
| 700 | 1 | |a Nishimura, Yoshihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Mori, Yasuko |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infectious diseases |d 1945 |g 226(2022), 8 vom: 17. Okt., Seite 1391-1395 |w (DE-627)NLM000005819 |x 1537-6613 |7 nnns |
| 773 | 1 | 8 | |g volume:226 |g year:2022 |g number:8 |g day:17 |g month:10 |g pages:1391-1395 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/infdis/jiac178 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 226 |j 2022 |e 8 |b 17 |c 10 |h 1391-1395 | ||